A repairing and firming composition for reshaping the collagen elastic network and its application

Abstract

This invention discloses a repairing and firming composition for reshaping the collagen elastic network and its application, belonging to the field of cosmetic technology. The composition comprises camellia flower extract and a complex nucleotide polypeptide, wherein the complex nucleotide polypeptide includes at least one selected from camellia PDRN, tripeptide-10 citrulline, acetyl tetrapeptide-9, and palmitoyl hexapeptide-14. This invention also discloses the application of this composition in repairing and firming cosmetics, and a repairing and firming face cream containing this composition. The components work synergistically to promote collagen synthesis, optimize collagen fiber arrangement, and inhibit collagen degradation, effectively reshaping the dermal collagen elastic network, thus providing skin repair, firming, and improved elasticity. Cellular experiments and human trials have confirmed that this composition has excellent skincare effects, and patch tests have verified that it is non-irritating and highly safe. This composition can be formulated into various dosage forms such as toners, lotions, masks, and serums, with a wide range of applications.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more particularly to a repairing and firming composition for reshaping the collagen elastic network and its application. Background Technology

[0002] Skin aging is a complex process involving the systemic degeneration of the extracellular matrix in the dermis, with the degradation of the collagen-elastin network being particularly crucial. With the accumulation of intrinsic aging and photoaging, the synthetic function of dermal fibroblasts gradually declines, the secretion rate of collagen decreases significantly, while the expression of matrix metalloproteinases continues to rise, leading to a degradation rate of collagen fibers far exceeding the rate of regeneration, resulting in net loss. Simultaneously, the remaining collagen fibers also deteriorate in quality: the originally regularly interwoven network structure becomes loose and twisted due to abnormal cross-linking, the gaps between fiber bundles increase, and the arrangement changes from highly ordered to disordered; collagen fibers also exhibit breakage, curling, and granulation due to enzymatic degradation and erroneous remodeling during repeated repair processes. This double blow of "reduction in quantity and quality" causes the dermis to lose its proper mechanical support and resilience, macroscopically manifesting as sagging skin, decreased elasticity, and blurred contours; in severe cases, it is accompanied by the loss of local tissue volume, forming depressions.

[0003] To address the aforementioned aging mechanisms, current anti-aging strategies in the skincare market primarily focus on two dimensions: 'supplementing exogenous collagen' and 'promoting endogenous collagen synthesis'. However, most of these strategies only aim to increase the quantity of collagen, failing to effectively intervene in the assembly quality and spatial arrangement of newly formed collagen fibers. Even if fibroblasts are activated and secrete sufficient collagen monomers, without proper microenvironmental guidance—such as correct integrin anchoring signals and sufficient basement membrane glycans and other small leucine-rich proteoglycans (SLRPs) to regulate fiber diameter and spacing—the newly synthesized collagen tends to accumulate randomly, unable to spontaneously rebuild the dense, orderly, and bi-directionally tensile three-dimensional elastic network structure of youth. In other words, simply "adding bricks" without "reinforcing the framework and adjusting the masonry method" may ultimately result in a pile of loose fibers lacking mechanical properties, making it difficult to truly reverse sagging and depressions. This explains why many anti-aging products claiming to "promote collagen" have limited and insufficiently lasting effects in actual use. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a repair and firming composition for reshaping the collagen elastic network and its application.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In a first aspect, the present invention provides a repairing and firming composition comprising Camellia chrysantha extract and a complex nucleotide polypeptide; wherein the complex nucleotide polypeptide comprises at least one of Camellia chrysantha PDRN, tripeptide-10 citrulline, acetyl tetrapeptide-9, and palmitoyl hexapeptide-14.

[0006] Preferably, the composition comprises the following components in parts by weight: Camellia chrysantha flower extract: 0.1-3 parts; Complex nucleotide polypeptides: 0.01-0.68 parts.

[0007] Preferably, the complex nucleotide polypeptide in the composition comprises the following parts by weight of raw materials: Camellia PDRN: 0.001-0.15 parts; Tripeptide-10 citrulline: 0.005-0.3 parts; Acetyl tetrapeptide-9: 0.002-0.15 parts; Palmitoyl hexapeptide-14: 0.001-0.08 parts.

[0008] In this composition, Camellia chrysantha flower extract is a plant extract rich in polyphenols and flavonoids, which exerts anti-aging and repairing effects on the skin through its antioxidant properties and collagen regeneration-promoting effects. Among the complex nucleotide peptides, PDRN is a polydeoxyribonucleotide derived from a specific source that accelerates skin damage repair and dermal regeneration by repairing cellular DNA and promoting collagen synthesis. Tripeptide-10 citrulline is a synthetic biomimetic peptide that improves the structural integrity of the dermal collagen network by regulating the regular arrangement and polymerization of collagen fibers. Acetyl tetrapeptide-9 is an acetylated signal peptide that enhances skin firmness and contour support by strengthening the dermal-epidermal junction (DEJ) and promoting collagen synthesis. Palmitoyl hexapeptide-14 is a palmitoylated active peptide that effectively restores skin elasticity and firmness by promoting the synthesis of collagen and elastin. Compared with a single core ingredient or a non-preferred ratio, the repair and firming composition of the present invention with a preferred ratio has more significant repair and firming effects.

[0009] Secondly, the present invention provides the use of the composition described in the first aspect in the preparation of cosmetics having repairing and firming effects.

[0010] Preferably, the cosmetic dosage form includes any one of toner, lotion, cream, mask, serum, and spray.

[0011] Thirdly, the present invention provides a face cream with repairing and firming effects, the face cream comprising the repairing and firming composition described in the first aspect.

[0012] Preferably, the face cream further includes a thickener, a moisturizer, an oil phase, an antioxidant, a pH adjuster, and deionized water.

[0013] Preferably, the thickener comprises at least one of the following: polyacrylate crosspolymer-6, carbomer, carrageenan, gellan gum, xanthan gum, microcrystalline cellulose, cellulose gum, ethyl cellulose, strychnine gum, guar gum, ammonium acryloyl dimethyl taurate / VP copolymer, acrylate copolymer, sclerotium gum, polyvinylpyrrolidone, amylopectin, and sodium polyacrylate. The moisturizer includes at least one of the following: glycerin, 1,2-butanediol, 1,4-butanediol, 1,2-hexanediol, 1,3-propanediol, 1,2-pentanediol, butylene glycol, caprylyl glycol, dipropylene glycol, tremella polysaccharide, trehalose, betaine, allantoin, hyaluronic acid, sodium hyaluronate, acetylated sodium hyaluronate, hydrolyzed sodium hyaluronate, sodium hyaluronate cross-linked polymer, β-glucan, budding short-stem polysaccharide, and ceramide. The pH adjuster includes at least one of arginine, tromethamine, disodium EDTA, and citric acid; The oil phase includes at least one of C14-22 alcohol, C12-20 alkyl glucoside, caprylic / capric triglyceride, hydrogenated lecithin, squalane, stearyltrimethylammonium chloride, cetearyl glucoside, cetearyl alcohol, and shea butter; The antioxidants include at least one of p-hydroxyacetophenone, vitamin C, vitamin E, astaxanthin, ergothioneine, tea polyphenols, propyl gallate, and proanthocyanidins.

[0014] Compared with the prior art, the beneficial effects of the present invention are as follows: The repairing and firming composition provided by this invention achieves a significant synergistic effect through the scientific ratio of Camellia chrysantha flower extract and complex nucleotide peptides. It can simultaneously address four core aspects: promoting the synthesis of type I collagen in dermal fibroblasts, strengthening the anchoring tension between fibroblasts and the collagen matrix, regulating the diameter and spatially ordered arrangement of collagen fibers, and inhibiting MMP-1-mediated collagen degradation. This comprehensively repairs and reshapes the dermal collagen elastic network, effectively reversing the problem of "quantity reduction and quality degradation" of skin collagen fibers, and achieving excellent anti-aging, firming, and repairing effects. Its efficacy indicators on dermal cells are significantly better than those of the control group with a single core ingredient, lack of core ingredients, or replacement of core ingredients.

[0015] The repairing and firming composition of this invention, when added to cosmetics, can significantly improve the skin barrier function, reduce transepidermal water loss (TEWL), and significantly increase the skin's firmness (F4) and elasticity (R2). Visible skin firming, improved elasticity, and barrier repair effects can be achieved within a 28-day usage cycle. Furthermore, its efficacy is significantly superior to the control group lacking core ingredients, having substituted core ingredients, or having formulations exceeding the specified range. Moreover, the composition's efficacy gradually increases with increasing addition amount within the range of 0.1%-1.0%, with an excellent repairing and firming effect achieved at 0.5%. Considering both cost and efficacy, it offers high cost-effectiveness.

[0016] The repairing and firming composition of the present invention and cosmetics containing the composition have been verified by human skin occlusive patch test. No adverse skin reactions such as erythema, edema, or papules were observed in any of the subjects. The products are gentle and non-irritating to human skin, have good compatibility, and can be widely used in various cosmetic formulations such as toners, lotions, creams, masks, serums, and sprays, adapting to different skin care scenarios and usage needs. Detailed Implementation

[0017] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0018] The sources of some of the raw materials used in this invention are as follows: Camellia chrysantha flower extract: batch number T078OI01, purchased from Shenzhen Viki Technology Co., Ltd.; Camellia PDRN: Batch number SCP25121201S, purchased from Jiangsu Ruiting Biotechnology Co., Ltd.; Tripeptide-10 Citrulline: Product code cxst10gas-2024, purchased from Shaanxi Chenxi Biotechnology Co., Ltd. Acetyl tetrapeptide-9: Product code XL-3321, purchased from Xi'an Xinlu Biotechnology Co., Ltd.; Palmitoyl hexapeptide-14: Product code HH9121JQRCVM, purchased from Xi'an Shilin Biotechnology Co., Ltd.; Unless otherwise specified, all other materials and reagents used in the examples are commercially available.

[0019] Preparation of complex nucleotide peptides Complex nucleotide polypeptide 1 Composed of the following components by mass: Camellia PDRN: 0.02 parts; Tripeptide-10 citrulline: 0.08 parts; Acetyl tetrapeptide-9: 0.02 parts; Palmitoyl hexapeptide-14: 0.02 parts; Preparation method: Mix the above raw materials evenly to obtain a complex nucleotide polypeptide.

[0020] Complex nucleotide polypeptide 2 Composed of the following components by mass: Camellia PDRN: 0.04 parts; Tripeptide-10 citrulline: 0.05 parts; Acetyl tetrapeptide-9: 0.04 parts; Palmitoyl hexapeptide-14: 0.01 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0021] Complex nucleotide polypeptide 3 Composed of the following components by mass: Camellia PDRN: 0.01 parts; Tripeptide-10 citrulline: 0.02 parts; Acetyl tetrapeptide-9: 0.01 parts; Palmitoyl hexapeptide-14: 0.005 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0022] Complex nucleotide polypeptide 4 Composed of the following components by mass: Camellia PDRN: 0.08 parts; Tripeptide-10 citrulline: 0.15 parts; Acetyl tetrapeptide-9: 0.08 parts; Palmitoyl hexapeptide-14: 0.05 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0023] Complex nucleotide polypeptide 5 Composed of the following components by mass: Camellia PDRN: 0.15 parts; Tripeptide-10 citrulline: 0.3 parts; Acetyl tetrapeptide-9: 0.002 parts; Palmitoyl hexapeptide-14: 0.08 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0024] Complex nucleotide polypeptide 6 Composed of the following components by mass: Camellia PDRN: 0.002 parts; Tripeptide-10 citrulline: 0.005 parts; Acetyl tetrapeptide-9: 0.15 parts; Palmitoyl hexapeptide-14: 0.001 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0025] Complex nucleotide polypeptide ① Composed of the following components by mass: Camellia PDRN: 0.2 parts; Tripeptide-10 citrulline: 0.002 parts; Acetyl tetrapeptide-9: 0.3 parts; Palmitoyl hexapeptide-14: 0.0005 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0026] Complex nucleotide polypeptide ② Composed of the following components by mass: Camellia PDRN: 0.001 parts; Tripeptide-10 citrulline: 0.5 parts; Acetyl tetrapeptide-9: 0.001 parts; Palmitoyl hexapeptide-14: 0.15 parts; The preparation method is the same as that for complex nucleotide polypeptide 1.

[0027] Complex nucleotide polypeptide ③ The only difference from complex nucleotide polypeptide 1 is that it lacks camellia PDRN, and the missing mass fraction is made up with tripeptide-10 citrulline, acetyl tetrapeptide-9 and palmitoyl hexapeptide-14 in a mass ratio of 4:1:1.

[0028] Complex nucleotide polypeptide ④ The only difference from complex nucleotide polypeptide 1 is that it lacks tripeptide-10 citrulline, and the missing mass fraction is made up by camellia PDRN, acetyl tetrapeptide-9, and palmitoyl hexapeptide-14 in a mass ratio of 1:1:1.

[0029] Complex nucleotide polypeptide ⑤ The only difference from complex nucleotide polypeptide 1 is that it lacks acetyl tetrapeptide-9, and the missing mass fraction is made up by camellia PDRN, tripeptide-10 citrulline, and palmitoyl hexapeptide-14 in a mass ratio of 1:4:1.

[0030] Complex nucleotide polypeptides⑥ The only difference from complex nucleotide polypeptide 1 is that it lacks palmitoyl hexapeptide-14, and the missing mass fraction is made up with camellia PDRN, tripeptide-10 citrulline and acetyl tetrapeptide-9 in a mass ratio of 1:4:1.

[0031] Complex nucleotide polypeptides⑦ The only difference from complex nucleotide peptide 1 is that yeast nucleotides (catalog number xk-250826123, Shanxi Xukang Biotechnology Co., Ltd.) are used instead of camellia PDRN.

[0032] Complex nucleotide polypeptide ⑧ The only difference from complex nucleotide peptide 1 is that tripept-1 copper (catalog number TH-0197, Xi'an Tianhe Pharmaceutical Co., Ltd.) is used instead of tripept-10 citrulline.

[0033] Complex nucleotide polypeptides ⑨ The only difference from complex nucleotide peptide 1 is that acetyl tetrapeptide-3 (catalog number SXBHSW003, Shaanxi Baohe Biotechnology Co., Ltd.) is used instead of acetyl tetrapeptide-9.

[0034] Complex nucleotide polypeptide ⑩ The only difference from complex nucleotide peptide 1 is that palmitoyl hexapeptide-12 (catalog number FZSW-1101-3, Shanxi Fenzhou Biotechnology Co., Ltd.) is used instead of palmitoyl hexapeptide-14.

[0035] Preparation of Repairing and Firming Composition Composition 1 Composed of the following components by mass: Camellia chrysantha flower extract: 1 part; Complex nucleotide polypeptide 1: 0.14 parts.

[0036] Preparation method: Camellia chrysantha flower extract and complex nucleotide peptides are mixed evenly at 25°C to obtain the composition.

[0037] Composition 2 Composed of the following components by mass: Camellia chrysantha flower extract: 0.5 parts; Complex nucleotide polypeptide 2: 0.14 parts.

[0038] The preparation method is the same as that of composition 1.

[0039] Composition 3 Composed of the following components by mass: Camellia chrysantha flower extract: 2 parts; Complex nucleotide polypeptide 3: 0.045 parts.

[0040] The preparation method is the same as that of composition 1.

[0041] Composition 4 Composed of the following components by mass: Camellia chrysantha flower extract: 0.2 parts; Complex nucleotide polypeptide 4: 0.36 parts.

[0042] The preparation method is the same as that of composition 1.

[0043] Composition 5 Composed of the following components by mass: Camellia chrysantha flower extract: 3 parts; Complex nucleotide polypeptide 5: 0.532 parts.

[0044] The preparation method is the same as that of composition 1.

[0045] Composition 6 Composed of the following components by mass: Camellia chrysantha flower extract: 0.1 parts; Complex nucleotide polypeptide 6: 0.158 parts.

[0046] The preparation method is the same as that of composition 1.

[0047] Comparative Example 1 Composed of the following components by mass: Camellia chrysantha flower extract: 5 parts; Complex nucleotide polypeptide ①: 0.5025 parts.

[0048] The preparation method is the same as that of composition 1.

[0049] Comparative Example 2 Composed of the following components by mass: Camellia chrysantha flower extract: 0.05 parts; Complex nucleotide polypeptide ②: 0.652 parts.

[0050] The preparation method is the same as that of composition 1.

[0051] Comparative Example 3 The only difference from composition 1 is that it does not contain Camellia chrysantha flower extract.

[0052] Comparative Example 4 The only difference from composition 1 is that it does not contain complex nucleotide peptides.

[0053] Comparative Example 5 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide 3 is used to replace complex nucleotide polypeptide 1.

[0054] Comparative Example 6 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ④ is used to replace complex nucleotide polypeptide 1.

[0055] Comparative Example 7 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ⑤ is used to replace complex nucleotide polypeptide 1.

[0056] Comparative Example 8 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ⑥ is used to replace complex nucleotide polypeptide 1.

[0057] Comparative Example 9 The only difference from composition 1 is that camellia flower extract (product number QH-SCHTQW0628, Shaanxi Qionghua Biotechnology Co., Ltd.) is used instead of golden camellia flower extract.

[0058] Comparative Example 10 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ⑦ is used to replace complex nucleotide polypeptide 1.

[0059] Comparative Example 11 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ⑧ is used to replace complex nucleotide polypeptide 1.

[0060] Comparative Example 12 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide ⑨ is used to replace complex nucleotide polypeptide 1.

[0061] Comparative Example 13 The only difference from composition 1 is that an equal mass fraction of complex nucleotide polypeptide 1 is used instead of complex nucleotide polypeptide 1.

[0062] Preparation of a face cream with repairing and firming effects The preparation method of face cream base is as follows: (1) Mix phase A with deionized water and stir. Heat to 85°C and homogenize at 1300 rpm for 4 min. After homogenization, keep warm for later use to obtain pre-prepared phase A. (2) Mix the B phase, heat it to 75°C, and homogenize it at 1300 rpm for 4 min. After homogenization, keep it warm for later use to obtain the pre-made B phase; (3) Mix the C phase, heat to 60°C and stir until homogeneous to obtain the pre-prepared C phase; (4) Heat the pre-prepared phase A to 80°C, add the pre-prepared phase B at 250 rpm, stir and mix evenly, then cool down to 60°C, add the pre-prepared phase C at 250 rpm and stir and mix, then cool down to 40°C, add phase D to adjust the pH to 6.0, then stop stirring, discharge the material, and obtain the face cream base. The composition and mass percentage of phases A, B, C, and D are shown in Table 1.

[0063] Table 1. Raw materials and their percentage by weight in the face cream base.

[0064] Preparation of a face cream with repairing and firming effects The preparation method for a face cream with repairing and firming effects is as follows: Heat the cream base to 40°C, then add the repair and firming composition, stir well, cool to room temperature, stop stirring, and discharge to obtain the repair and firming cream.

[0065] The serial numbers of the above-mentioned repair and firming compositions and the respective mass percentages of the repair and firming compositions and the face cream base are shown in Table 2.

[0066] Table 2. Serial Number of Repairing and Firming Composition in Face Cream and Mass Percentage of Repairing and Firming Composition and Face Cream Base Application Example 1 0.5 Composition 1 margin Application Example 2 0.5 Composition 2 margin Application Example 3 0.5 Composition 3 margin Application Example 4 0.5 Composition 4 margin Application Example 5 0.5 Composition 5 margin Application Example 6 0.5 Composition 6 margin Application Example 7 0.1 Composition 1 margin Application Example 8 1.0 Composition 1 margin Compare and contrast with example 1-13 0.5 Comparative Examples 1-13 margin Blank application example 0 - margin Note: The correspondence between Comparative Application Examples 1-13 and Comparative Examples 1-13 is as follows: Comparative Application Example 1 uses the repair and firming composition with the serial number of Comparative Example 1, and so on, Comparative Application Example 13 uses the repair and firming composition with the serial number of Comparative Example 13; the blank application examples do not contain the repair and firming composition, but only the cream base.

[0067] Efficacy test Test Example 1: Effects of the Repairing and Firming Composition on Dermal Cells Experimental materials: The cell line used was human dermal fibroblast HDF (catalog number PC-202h, Wuhan Saisuo Biotechnology Co., Ltd.). The test conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide concentration 5±1%. Cells were cultured and treated according to groups, and then the contents of type I collagen, integrin, basement membrane glycan, and matrix metalloproteinase MMP-1 were detected. The test methods are as follows: The specific testing method is as follows: (1) Inoculation: Human dermal fibroblasts (HDF) were inoculated at a rate of 1×10⁻⁶. 5 The cells were seeded at a density of 100 cells / mL into T25 culture flasks, and 5 mL of DMEM high-glucose culture medium (Gibco) containing 10% fetal bovine serum was added to each flask. The cells were incubated at 37°C and 5% CO2 for 24 h until the cell confluence reached 80%-85%. (2) Induction: Discard the culture medium, add PBS buffer, and irradiate the cells with a T8-15W UVA lamp at a height of 25cm. The irradiation dose is set to 9J / cm² and the irradiation time is 75min. (3) Sample feeding: Discard the buffer solution. Add DMEM high glucose culture medium containing 10% fetal bovine serum to the control group and add DMEM high glucose culture medium containing 10% fetal bovine serum and 20 μg / mL of repair and firming composition to the sample group. After culturing for 24 h, collect the cells from each group, discard the supernatant, and lyse the cells with RIPA lysis buffer containing protease inhibitor (Shanghai Merck, V900854) at 4℃. Centrifuge the lysed sample at 12000×g for 5 minutes and take the supernatant. (4) Detection of type I collagen content: The type I collagen content of each group was detected using the human type I collagen (ColI) ELISA kit (catalog number ml057630, Shanghai Enzyme-Linked Biotechnology). The specific operation was to follow the instructions of the kit, take equal amounts of supernatant and add them to the corresponding reaction wells of the kit. After incubation, washing, color development and other steps, the absorbance OD value was measured at a specific wavelength using an ELISA reader. The content of type I collagen in each group was calculated according to the standard curve. (5) Integrin content detection: The integrin content of each group was detected using the human integrin A11 (ITGA11) kit (catalog number ml098749, Shanghai Enzyme-Linked Biotechnology). The specific operation was to follow the instructions of the kit, take equal amounts of supernatant and add them to the corresponding reaction wells of the kit. After incubation, washing, color development and other steps, the absorbance OD value was measured at a specific wavelength using an ELISA reader. The integrin content of each group was calculated according to the standard curve. (6) Detection of basement membrane glycan content: The basement membrane glycan content of each group was detected using the human basement membrane glycan (LUM) ELISA kit (catalog number ml105537, Shanghai Enzyme-Linked Biotechnology). The specific operation was to follow the instructions of the kit, take equal amounts of supernatant and add them to the corresponding reaction wells of the kit, and after incubation, washing, color development and other steps, use an ELISA reader to measure the absorbance OD value at a specific wavelength, and calculate the basement membrane glycan content of each group according to the standard curve. (7) Detection of matrix metalloproteinase MMP-1 content: The content of matrix metalloproteinase 1 (MMP-1) in each group was detected using the human matrix metalloproteinase 1 (MMP-1) ELISA kit (catalog number ml038199, Shanghai Enzyme-Linked Biotechnology). The specific operation was to follow the instructions of the kit, take equal amounts of supernatant and add them to the corresponding reaction wells of the kit, and after incubation, washing, and color development, use an ELISA reader to measure the absorbance OD value at a specific wavelength. The content of matrix metalloproteinase MMP-1 in each group was calculated according to the standard curve.

[0068] This experiment aimed to evaluate the multidimensional regulatory effect of the repair and firming composition on the dermal collagen elastic network. Four key indicators were selected: type I collagen, integrin, basement membrane glycan, and matrix metalloproteinase-1, which correspond to four anti-aging links: collagen regeneration, structural compactness, orderly arrangement, and anti-degradation, respectively. Type I collagen is the most abundant structural protein in the extracellular matrix of dermal cells. Its content directly reflects the collagen synthesis capacity of fibroblasts and is the most direct evidence for measuring "collagen regeneration." Integrins (represented by ITGA11) are proteins on the surface of fibroblasts that recognize and bind collagen, strengthening the adhesion and tension coupling of fibroblasts to the collagen matrix, thereby "tightening" the collagen network. Lumican belongs to the small leucine-rich proteoglycan family and regulates the diameter and spatial arrangement of collagen fibers through specific binding to the surface of collagen fibers, making it a key regulatory factor in maintaining "orderly arrangement." Matrix metalloproteinase-1 (MMP-1) is the main enzyme that degrades type I collagen. A decrease in its activity or content directly reflects a weakening of extracellular matrix catabolism, i.e., "preventing collagen degradation." Simultaneous detection of these four indicators can comprehensively verify the efficacy of the sample in promoting collagen regeneration, tightening collagen structure, optimizing fiber ordering, and inhibiting matrix degradation.

[0069] The anti-aging ability of the repairing and firming composition is represented by the improvement of various indicators, calculated using the following formula: Type I collagen improvement rate = (Type I collagen sample group - Type I collagen control group) / Type I collagen control group × 100%; Integrin improvement rate = (Integrin content sample group - Integrin content control group) / Integrin content control group × 100%; Improvement rate of basement membrane polysaccharide content = (basement membrane polysaccharide content sample group - basement membrane polysaccharide content control group) / basement membrane polysaccharide content control group × 100%; Improvement rate of matrix metalloproteinase MMP-1 = (MMP-1 content control group - MMP-1 content sample group) / MMP-1 content control group × 100%; The test results are shown in Table 3.

[0070] Table 3. Effects of the Repairing and Firming Composition on Dermal Cells Composition 1 152.9 63.5 113.7 84.9 Composition 2 145.3 64.1 115.2 81.2 Composition 3 124.8 53.9 91.6 75.3 Composition 4 109.2 59.4 100.5 73.7 Composition 5 87.4 42.8 79.4 63.6 Composition 6 82.6 49.7 86.8 59.5 Comparative Example 1 55.2 28.3 54.1 36.4 Comparative Example 2 44.6 26.7 53.9 34.8 Comparative Example 3 31.5 32.4 52.7 22.6 Comparative Example 4 38.2 19.6 29.5 26.7 Comparative Example 5 54.7 31.2 59.4 33.1 Comparative Example 6 59.3 24.5 43.6 37.4 Comparative Example 7 52.8 25.1 47.2 32.3 Comparative Example 8 57.5 32.8 51.5 36.2 Comparative Example 9 34.6 35.3 53.2 24.4 Comparative Example 10 55.1 34.7 60.3 36.5 Comparative Example 11 60.4 26.2 46.8 41.2 Comparative Example 12 53.6 28.9 50.1 35.8 Comparative Example 13 58.7 34.4 52.5 39.6 The improvement rates of type I collagen, integrin, basement membrane glycan, and MMP-1 in compositions 1-6 of this invention are significantly higher than those of all comparative examples. The improvement rate of type I collagen in composition 1 even reaches 152.9%, far exceeding that of comparative examples 3 and 4, which contain only a single core component. It is also significantly higher than other comparative examples that lack core peptides, replace core raw materials, or have a ratio exceeding the scope of this invention. This fully demonstrates that there is a significant synergistic effect between Camellia chrysantha extract and complex nucleotide peptides. After scientific formulation, the two can simultaneously achieve comprehensive repair and remodeling of the dermal collagen elastic network from four core dimensions: promoting collagen regeneration, strengthening the anchoring tension between cells and collagen, regulating the orderly arrangement of collagen fibers, and inhibiting collagen degradation. Moreover, the formulation range defined by this invention can achieve a better level of efficacy. Deviating from this range or replacing core raw materials will lead to a significant decrease in efficacy.

[0071] Test Example 2: Human Skin Patch Test Sixty volunteers were recruited, 30 men and 30 women, aged 20-50 years, and randomly divided into two groups of 15 men and 15 women each. A closed patch test was used. Equal amounts (0.020g-0.025g) of test samples (face creams prepared in Examples 1-8, Control Examples 1-13, and the blank example) were placed in patch applicators. The patches were then applied to the volunteers' arms with hypoallergenic adhesive tape, gently pressed to ensure even application, and left for 24 hours. The blank control group consisted of distilled water. One patch applicator was applied to each arm of each volunteer. Each patch applicator had 10 holes, allowing for the simultaneous testing of 20 samples per volunteer (both arms). The first group used face creams prepared in Examples 1-8 and the blank example, while the second group used face creams prepared in Control Examples 1-13 and the blank example. A blank control group was included in each group. After 24 hours, the patch applicator was removed, and skin reactions were observed and recorded at 0.5 hours, 24 hours, and 48 hours. The criteria for judging the severity of adverse skin reactions are shown in Table 4.

[0072] Table 4 Adverse Reaction Levels 0 negative reaction 1 Suspicious reaction, only slight erythema 2 Weak positive reaction (erythema reaction): erythema, infiltration, edema, and papules may be present. 3 Strong positive reaction (herpes reaction): erythema, infiltration, edema, papules; the reaction may extend beyond the test area. 4 Extremely strong positive reaction (confluent herpes simplex reaction): obvious erythema, severe infiltration, edema, confluent herpes simplex; reaction extends beyond the test area. After testing, the face creams provided in Application Examples 1-8, Comparative Application Examples 1-13, and Blank Application Examples of the present invention all showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0073] Test Example 3: Composition Repair and Firming Human Body Efficacy Test Experimental Methods: 132 Asian adult volunteers aged 25-60 years were selected. Inclusion criteria were: (1) self-reported history of skin sensitivity (confirmed by expert evaluation); (2) transepidermal water loss (TEWL) > 20 g / (m²•h), indicating skin barrier damage; (3) obvious sagging and decreased elasticity of facial skin; (4) no use of anti-aging or firming skincare products in the past 3 months; (5) no history of skin diseases or cosmetic allergies. The volunteers were randomly divided into 22 groups of 6 people each. The volunteers applied 0.5g of the sample to their entire face twice a day, morning and evening (the samples were face creams prepared from application examples 1-8, control application examples 1-13, and blank application examples). Data were collected before use (D0) and 28 days after use (D28). After arriving at the site, volunteers washed their faces with a cleansing facial wash and sat quietly for 30 minutes in an air-conditioned room with a temperature of 21±1℃ and a humidity of 50±10%. Researchers then used a skin moisture loss test probe (TewaMeter®TMHex) to measure the transepidermal water loss (TEWL) value of the cheekbone and a cutometer (MPA580, Courage+Khazaka, Germany) to measure the firmness (F4) and elasticity (R2) value of the cheek. Each measurement was repeated 3 times, and the average value was taken.

[0074] The repair ability of the sample is represented by the improvement in the TEWL value, and the firming ability is represented by the improvement in the F4 value and R2 value, as shown in the following formula: TEWL value improvement rate = (TEWL) D0 -TEWL D28 ) / TEWL D0 ×100%; F4 value improvement rate = (F4 D0 -F4 D28 ) / F4 D0 ×100%; R² improvement rate = (R²) D28 -R2 D0 ) / R2 D0 ×100%.

[0075] The results are shown in Table 5.

[0076] Table 5. Results of Human Efficacy Tests for Repairing and Firming Face Cream Blank application example 0.3 0.0 0.1 Application Example 1 24.1 29.4 32.6 Application Example 2 25.4 30.1 31.1 Application Example 3 20.7 26.3 28.5 Application Example 4 23.1 27.4 27.8 Application Example 5 18.8 23.1 25.2 Application Example 6 15.5 25.8 24.7 Application Example 7 17.2 22.1 24.3 Application Example 8 25.6 31.3 34.9 Comparative Application Example 1 9.3 13.4 14.8 Comparative Application Example 2 6.7 11.6 7.9 Comparative Application Example 3 6.4 16.2 3.8 Comparative Application Example 4 5.1 5.5 6.7 Comparative Application Example 5 6.1 16.7 14.0 Comparative Application Example 6 11.4 8.3 17.1 Comparative Application Example 7 9.4 9.2 10.6 Comparative Application Example 8 9.6 15.6 16.1 Comparative Application Example 9 7.0 16.9 5.5 Comparative Application Example 10 6.7 17.5 14.4 Comparative Application Example 11 12.2 8.8 17.6 Comparative Application Example 12 9.8 12.2 12.7 Comparative Application Example 13 10.8 16.4 16.9 The improvement rates of TEWL, F4, and R2 values ​​in Application Examples 1-8 of this invention were significantly higher than those in the blank application examples and all comparative application examples. Application Example 1, within a 28-day usage period, achieved a TEWL improvement rate of 24.1%, an F4 improvement rate of 29.4%, and an R2 improvement rate of 32.6%, indicating that the repairing and firming composition of this invention, when added to a face cream, can simultaneously achieve excellent skin barrier repair, firmness enhancement, and elasticity restoration effects. Meanwhile, the results of Application Examples 7-8 show that the composition exhibits good repairing and firming effects within an addition range of 0.1%-1.0%, demonstrating extremely high cost-effectiveness. In contrast, in the comparative application examples, face creams lacking core ingredients, with substituted core ingredients, or with proportions exceeding the limits defined by this invention showed a significant decrease in their repairing and firming effects, further verifying the synergistic effect between the core ingredients of the composition of this invention, as well as the scientific nature and superiority of the formula of this invention.

[0077] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A repairing and firming composition, characterized in that, The composition comprises Camellia chrysantha flower extract and a complex nucleotide polypeptide; the complex nucleotide polypeptide comprises at least one of Camellia chrysantha PDRN, tripeptide-10 citrulline, acetyl tetrapeptide-9, and palmitoyl hexapeptide-14.

2. The composition according to claim 1, characterized in that, The composition comprises the following components in parts by weight: Camellia chrysantha flower extract: 0.1-3 parts; Complex nucleotide polypeptides: 0.01-0.68 parts.

3. The composition according to claim 1 or 2, characterized in that, The complex nucleotide polypeptide comprises the following raw materials in parts by weight: Camellia PDRN: 0.001-0.15 parts; Tripeptide-10 citrulline: 0.005-0.3 parts; Acetyl tetrapeptide-9: 0.002-0.15 parts; Palmitoyl hexapeptide-14: 0.001-0.08 parts.

4. The use of the composition according to any one of claims 1-3 in the preparation of a cosmetic having repairing and firming effects.

5. The application as described in claim 4, characterized in that, The cosmetic dosage forms include any one of the following: toner, lotion, cream, mask, serum, and spray.

6. A face cream with repairing and firming effects, characterized in that, The face cream comprises the repairing and firming composition according to any one of claims 1-3.

7. The face cream as described in claim 6, characterized in that, The face cream also includes thickeners, moisturizers, oil phases, antioxidants, pH adjusters, and deionized water.

8. The face cream as described in claim 7, characterized in that, The thickener includes at least one of the following: polyacrylate crosspolymer-6, carbomer, carrageenan, gellan gum, xanthan gum, microcrystalline cellulose, cellulose gum, ethyl cellulose, strychnine gum, guar gum, ammonium acryloyl dimethyl taurate / VP copolymer, acrylate copolymer, sclerotium gum, polyvinylpyrrolidone, amylopectin, and sodium polyacrylate.

9. The face cream as described in claim 7, characterized in that, The moisturizer includes at least one of the following: glycerin, 1,2-butanediol, 1,4-butanediol, 1,2-hexanediol, 1,3-propanediol, 1,2-pentanediol, butylene glycol, caprylyl glycol, dipropylene glycol, tremella polysaccharide, trehalose, betaine, allantoin, hyaluronic acid, sodium hyaluronate, acetylated sodium hyaluronate, hydrolyzed sodium hyaluronate, sodium hyaluronate cross-linked polymer, β-glucan, budding short-stem polysaccharide, and ceramide.

10. The face cream as described in claim 7, characterized in that, The pH adjuster includes at least one of arginine, tromethamine, disodium EDTA, and citric acid; The oil phase includes at least one of C14-22 alcohol, C12-20 alkyl glucoside, caprylic / capric triglyceride, hydrogenated lecithin, squalane, stearyltrimethylammonium chloride, cetearyl glucoside, cetearyl alcohol, and shea butter; The antioxidants include at least one of p-hydroxyacetophenone, vitamin C, vitamin E, astaxanthin, ergothioneine, tea polyphenols, propyl gallate, and proanthocyanidins.

Images